Baastrup’s disease is a rare condition of the vertebral column often misdiagnosed and wrongly treated due to poor knowledge, characterized by low back pain arising from the close approximation of adjacent posterior spinous processes and resultant degenerative changes. Diagnosis rests on clinical examination and detailed imaging studies. Proposed therapies include conservative treatment, percutaneous infiltrations or surgical therapies. We present the case of a 31-year-old man with persistent chronic lumbago for several years. In whom, the diagnosis of Baastrup’s disease was high suspected clinically, with a final surgical treatment despite the absence of inflammation on imaging studies, which allowed the diagnostic confirmation and the return to a normal social and professional life. We wish through this case, to expose the different steps of interventional diagnostic/therapeutical procedures until the surgical management in a clinical suspicion of Baastrup’s diseases with unclear radiological findings.
Background and Objectives: Dexmedetomidine, an alpha-2 agonist, is used as an adjunct to anesthesia in enhanced recovery after surgery (ERAS) programs. One of its advantages is the opioid-sparing effect which can facilitate early extubation and recovery. When the ERAS cardiac society was set in 2017, our facility was already using the ERAS program, in which the “fast-track Anesthesia” was facilitated by the intraoperative infusion of dexmedetomidine. Our objective is to share our experience and investigate the potential impact of intraoperative dexmedetomidine use as a part of the ERAS program on patient outcomes in elective cardiac surgery. Materials and Methods: An observational retrospective cohort study was conducted at a university hospital in Switzerland. The patients who underwent elective cardiac surgery with cardiopulmonary bypass between 1 June 2017 and 31 August 2018 were included in this analysis (n = 327). Regardless of the surgery type, all the patients received a standardized fast-track anesthesia protocol inclusive of dexmedetomidine infusion, reduced opioid dose, and parasternal nerve block. The primary outcome was the postoperative time when the criteria for extubation were met. Three groups were identified: group 0—(extubated in the operating room), group < 6 (extubated in less than 6 h), and group > 6 (extubated in >6 h). The secondary outcomes were adverse events, length of stay in ICU and in hospital, and total hospitalization costs. Results: Dexmedetomidine was well-tolerated, with no significant adverse events reported. Early extubation was performed in 187 patients (57%). Group 3 had a significantly longer length of stay in the ICU (median: 70 h vs. 25 h) and in hospital (17 vs. 12 days), and consequently higher total hospitalization costs (CHF 62,551 vs. 38,433) compared to the net data from the other two groups (p < 0.0001). Conclusions: Our findings suggest that dexmedetomidine can be safely used as part of the opioid-sparing anesthesia protocol in patients undergoing elective cardiac surgery with cardiopulmonary bypass with the potential to facilitate early extubation, shorter ICU and hospital stays, and reduced hospitalization costs.
1 January 2025 in Computational and Structural Biotechnology Journal
Summary: Purpose: This prospective observational clinical study investigated discrepancy between noninvasive continuous haemoglobin (SpHb, Masimo Corp., Irvine, CA) measurements with sensors placed on three fingertips during elective cardiac surgery. Materials and methods: The study included 12 adult patients who underwent elective coronary artery bypass grafting (CABG) under cardiopulmonary bypass (CPB). Three identical versions of SpHb sensors were placed on the fingers of the same hand and connected to dedicated Masimo Radical-7 monitors. Data were continuously recorded throughout the surgery. Multiple group comparison tests—Kruskal Wallis and Alexander Govern tests—were used to compare three sets of SpHb data (trends). Bland Altman and Giavarina plots were used to compare the SpHb data with invasive arterial haemoglobin (Lab-Hb) data obtained at clinically relevant time points chosen at the discretion of the cardiac anaesthesiologist, who was blinded to the study protocol. Results: There was a good correlation between the time-matched SpHb data from the three sensors at 253 time points (r = 0.86–0.95), but there was a significant difference between the SpHb values obtained from each sensor and the average SpHb value of all 3 sensors (p < 0.05) at each time point. The absolute difference between the SpHb value obtained from each sensor and the average SpHb value was 0.69 g/dl g/dl (SD 1.49 g/dl). The accuracy and precision of the average SpHb for estimating Lab-Hb was higher compared to the SpHb values obtained from two out of three individual sensors (sn1 and sn3) and very similar compared to values obtained from sensor sn2. Conclusion: The sensor placement site can impact the SpHb measurement causing discrepancy between SpHb measured in different fingers. The average SpHb from three fingertips appears to be more accurate and precise in estimating Lab-Hb. However, more advanced sensors are needed.